Similarly, the CANTOS trial and related studies using IL‐1β monoclonal antibodies demonstrated that targeting chronic inflammation reduced cardiovascular risk, particularly in CKD patients, although at the cost of increased infection‐related mortality [72, 73]. The gene discussed is IL1B; the disease is infection.